Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125285591 | 12528559 | 1 | I | 20160312 | 20160317 | 20160705 | 20160705 | EXP | GR-PFIZER INC-2016164031 | PFIZER | 70.00 | YR | M | Y | 57.00000 | KG | 20160705 | MD | GR | GR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125285591 | 12528559 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | AUC 6 | 76517 | ||||||||||
| 125285591 | 12528559 | 2 | SS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | 452 MG, UNK | 76517 | 452 | MG | ||||||||
| 125285591 | 12528559 | 3 | SS | BLINDED BEVACIZUMAB | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | 945 MG, EVERY 21 DAYS | 3780 | MG | 0 | 945 | MG | SOLUTION FOR INFUSION | Q3W | ||||
| 125285591 | 12528559 | 4 | SS | BLINDED BEVACIZUMAB | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | 945 MG, EVERY 21 DAYS | 3780 | MG | 0 | 945 | MG | SOLUTION FOR INFUSION | Q3W | ||||
| 125285591 | 12528559 | 5 | SS | BLINDED PF-06439535 | INVESTIGATIONAL PRODUCT | 1 | Intravenous (not otherwise specified) | 945 MG, EVERY 21 DAYS | 3780 | MG | 0 | 945 | MG | SOLUTION FOR INFUSION | Q3W | ||||
| 125285591 | 12528559 | 6 | SS | BLINDED PF-06439535 | INVESTIGATIONAL PRODUCT | 1 | Intravenous (not otherwise specified) | 945 MG, EVERY 21 DAYS | 3780 | MG | 0 | 945 | MG | SOLUTION FOR INFUSION | Q3W | ||||
| 125285591 | 12528559 | 7 | SS | TAXOL | PACLITAXEL | 1 | Intravenous (not otherwise specified) | 200 MG/M2, UNK | 0 | 200 | MG/M**2 | ||||||||
| 125285591 | 12528559 | 8 | SS | TAXOL | PACLITAXEL | 1 | Intravenous (not otherwise specified) | 324 MG, UNK | 0 | 324 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125285591 | 12528559 | 1 | Non-small cell lung cancer |
| 125285591 | 12528559 | 3 | Non-small cell lung cancer |
| 125285591 | 12528559 | 4 | Non-small cell lung cancer |
| 125285591 | 12528559 | 5 | Non-small cell lung cancer |
| 125285591 | 12528559 | 6 | Non-small cell lung cancer |
| 125285591 | 12528559 | 7 | Non-small cell lung cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125285591 | 12528559 | HO |
| 125285591 | 12528559 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125285591 | 12528559 | Febrile neutropenia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125285591 | 12528559 | 1 | 20160104 | 0 | ||
| 125285591 | 12528559 | 2 | 20160307 | 20160307 | 0 | |
| 125285591 | 12528559 | 3 | 20160104 | 20160307 | 0 | |
| 125285591 | 12528559 | 4 | 20160104 | 20160307 | 0 | |
| 125285591 | 12528559 | 5 | 20160104 | 20160307 | 0 | |
| 125285591 | 12528559 | 6 | 20160104 | 20160307 | 0 | |
| 125285591 | 12528559 | 7 | 20160104 | 0 | ||
| 125285591 | 12528559 | 8 | 20160307 | 20160307 | 0 |